The Vaxart bivalent norovirus vaccine consists of an oral norovirus GI.1 vaccine tablet and an oral norovirus GII.4 vaccine tablet administered concurrently.
The bivalent norovirus Phase 1b trial includes two stages, an open-label lead-in phase which was completed successfully earlier this month, and a randomised, double-blind, placebo-controlled phase which has now started. Both portions of the trial are designed to evaluate safety and immunogenicity.
The company expects to receive topline data from the trial in the second half of 2019.
Norovirus is recognised as the leading cause of acute gastroenteritis in the United States.
It is a common intestinal infection that typically lasts three to five days and is marked by diarrhea, vomiting, abdominal cramps, nausea and sometimes fever.
Symptoms can be more severe in older adults and young children and may lead to serious complications including death.
Norovirus causes frequent and widespread outbreaks in the military, food industry, travel industry, child care facilities, elderly homes and healthcare facilities.
The US Centers for Disease Control and Prevention estimates that norovirus causes approximately 19m to 21m illnesses in the United States each year, resulting in 56,000 to 71,000 hospitalizations and 570 to 800 deaths, mostly among young children and older adults.
In a recent study by Johns Hopkins University and the CDC, researchers estimated global economic impact of norovirus disease at USD 60bn, USD 34bn of which occurred in high income countries, including the United States, Europe and Japan.
Vaxart is a biotechnology company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform.
The company's vaccines are designed to generate broad and durable immune responses that protect against a range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer. Vaxart's vaccines are administered using a convenient room temperature-stable tablet, rather than by injection.
Vaxart said it believes that tableted vaccines are easier to distribute and administer than injectable vaccines and have the potential to significantly increase vaccination rates.
Vaxart's development programmes include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus, as well as a therapeutic vaccine for human papillomavirus.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review